FDA Approves Vyvanse (lisdexamfetamine dimesylate) Capsules CII for the Treatment of ADHD in Adolescents
Links shared publicly online about this topic.
- 724total visits
FDA Approves Vyvanse (lisdexamfetamine dimesylate) Capsules CII for the Treatment of ADHD in Adolescents
View full resource at drugs.com
Tags: ADHD, ADHD Medication, Drug, FDA, Vyvanse
Most Recently Shared on November 15, 2010 at 11:03 pm By:
FDA Approves Vyvanse (lisdexamfetamine dimesylate) Capsules CII for the Treatment of ADHD in Adolescents: ... http://bit.ly/c1yPph #drug
PR-CANADA.net - FDA Approves Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the Treatment of ADHD in Adoles
pr-canada.net — “Free Press Release Distribution...” View full resource at pr-canada.net
Most Recently Shared on November 18, 2010 at 8:34 pm By:
Peter H Brown Doctor and Psychologist
FDA Approves Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the ... http://bit.ly/auRoIX #ADHD
FDA Approves Vyvanse (lisdexamfetamine dimesylate) Capsules CII for the Treatment of ADHD in Adolescents
drugs.com — “Vyvanse (lisdexamfetamine) is used to treat ADHD. Includes Vyvanse side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on November 15, 2010 at 10:57 pm By:
FDA Approves Vyvanse (lisdexamfetamine dimesylate) for the Treatment of ADHD in Adolescents - http://bit.ly/9kNj6A
Shire announces FDA approval of Vyvanse Capsules CII for ADHD in adolescents
news-medical.net — “Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents ages 13 to 17. The approval is based on study data demonstrating that Vyvanse improved ADHD symptoms compared to placebo in adolescents with ADHD. Vyvanse is also indicated for the treatment of ADHD i” View full resource at news-medical.net
Most Recently Shared on November 15, 2010 at 3:49 pm By:
Shire announces FDA approval of Vyvanse Capsules CII for ADHD in adolescents: Shire plc, the global specialty bi... http://bit.ly/a0SfMQ
FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant... -- PHILADELPHIA, May 4 /PRNewswire-FirstCall/ --
prnewswire.com — “FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD. First Oral Long-Acting ADHD Stimulant Treatment To Have Efficacy Data for Adults at 14-hours Postdose in Product Labeling.” View full resource at prnewswire.com
Most Recently Shared on May 4, 2010 at 2:33 pm By:
Peter H Brown Doctor and Psychologist
FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate ... http://bit.ly/9FWW5P #ADHD
Advertisement
